Pilot Trial to Assess the Performance and Tolerance of mRDX-02-17 Dermal Filler in the Facial Rejuvenation

NACompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

October 29, 2018

Primary Completion Date

February 14, 2019

Study Completion Date

February 24, 2019

Conditions
Facial Rejuvenation
Interventions
DEVICE

mRDX-02-17

"mRDX -02-17 is a dermal filler recommended for the correction and treatment of wrinkles and dermal depressions.~It is a sterile and viscous aqueous solution of hyaluronic acid in a concentration of 1.5% (p/v) with acetyl tetrapeptide-9 and palmitoyl tripeptide-5, as auxiliary ingredients which is administrated by intradermal injections.~This medical device encourages repair and restructuring of skin tissue and reduces the signs of aging.~mRDX -02-17 is indicated for patients with hypotrophic tissues, Crow's feet, Glogau III-IV, all skin photo types (Fitzpatrick I - VI) and a WSRS score (Wrinkle Severity Ranking Scale) from 2 to 5."

Trial Locations (2)

300209

Societatea Civila Medicala Doctor Rosu, Timișoara

300551

Hyperclinica Medlife Sucursala Timisoara, Timișoara

All Listed Sponsors
collaborator

Opera CRO, a TIGERMED Group Company

OTHER

lead

Mesoestetic Pharma Group S.L.

INDUSTRY

NCT03537456 - Pilot Trial to Assess the Performance and Tolerance of mRDX-02-17 Dermal Filler in the Facial Rejuvenation | Biotech Hunter | Biotech Hunter